Moksacin 5 Mg/Ml Kapi (Moxifloxacin Hydrochloride)

Moxifloxacin Hydrochloride, the active ingredient in Moksacin 5 Mg/Ml Kapi, is a fluoroquinolone antibiotic presented as a 5 mg/mL eye‑drop solution for ocular use. It treats bacterial conjunctivitis, keratitis and other bacterial ocular infections in patients requiring topical antibacterial therapy.

GNH USA supplies Moksacin 5 Mg/Ml Kapi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Moksacin (moxifloxacin hydrochloride) is used to treat bacterial infections of the eye and related structures.

- Bacterial conjunctivitis: reduces bacterial load and accelerates symptom resolution. - Keratitis: eradicates causative bacteria, promoting corneal healing. - Other bacterial ocular infections: provides broad‑spectrum coverage for various bacterial pathogens affecting the eye.

Adverse reactions may occur with ocular use of Moksacin.

Common Side Effects: - Eye irritation: transient burning or stinging sensation. - Redness: mild conjunctival hyperemia. - Tearing: increased lacrimation. - Foreign‑body sensation: feeling of grit in the eye. - Blurred vision: temporary visual disturbance. - Pruritus: mild itching of the ocular surface.

Serious or Rare Side Effects: - Corneal ulceration: rare but severe corneal damage. - Anaphylaxis: systemic allergic reaction requiring immediate medical attention. - Stevens‑Johnson syndrome: severe mucocutaneous reaction. - Toxic keratopathy: damage to corneal epithelium. - Persistent visual loss: prolonged or irreversible vision impairment. - Endophthalmitis: intra‑ocular infection.

When prescribing Moksacin, consider the following safety measures.

- Allergy assessment: avoid use in patients with known hypersensitivity to fluoroquinolones. - Contact lens use: discontinue lenses during treatment to reduce irritation risk. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk, as safety data are limited. - Concomitant ocular drugs: evaluate for possible additive irritation when used with other topical agents. - Monitoring: advise patients to report persistent redness, pain, or vision changes promptly. - Store at room temperature: keep in the original container, protect from light and moisture.

Moksacin may interact with other ophthalmic agents or systemic medications.

Major Interactions (Avoid): - Anticholinergic eye drops: may reduce drug penetration and efficacy. - Topical corticosteroids: can mask signs of infection, delaying appropriate therapy.

Moderate Interactions (Monitor Closely): - Systemic fluoroquinolones: increased risk of additive toxicity, especially tendon disorders. - Non‑steroidal anti‑inflammatory eye drops: may increase ocular irritation. - Preservative‑containing solutions: potential for compounded ocular surface toxicity.